Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 7/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17615024 | 0.90 | HPGD (0.49) | HSD11B1HPGDPKMMGLLTSHR | |
| SCHEMBL17615050 | 0.89 | HPGD (0.50) | HSD11B1HPGDPKMMGLLTSHR | |
| SCHEMBL17615094 | 0.85 | HPGD (0.69) | HSD11B1HPGDPKMTSHRMAPT | |
| SCHEMBL17615087 | 0.85 | HPGD (0.64) | HSD11B1HPGDPKMMAPT | |
| SCHEMBL17615025 | 0.84 | PKM (0.71) | HPGDPKMNPSR1MAPT | |
| SCHEMBL17615037 | 0.84 | HPGD (0.50) | HSD11B1HPGDPKMMGLLTSHR | |
| SCHEMBL17615012 | 0.84 | HPGD (0.67) | HSD11B1HPGDPKMTSHRMAPT | |
| SCHEMBL6279698 | 0.84 | HPGD (0.71) | HSD11B1HPGDPKMMGLLTSHR | |
| SCHEMBL17615020 | 0.83 | HPGD (0.45) | HSD11B1HPGDPKMMGLLTSHR | |
| SCHEMBL17615022 | 0.82 | HPGD (0.49) | HSD11B1HPGDPKMLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | NOS2, NOS3, NOS1 | HSD11B1 91/4885HPGD 17/4885PKM 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.